Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging scientific and clinical trial facilities at the University of Southampton and Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen’s business strategy is the realisation of value via licensing transactions – validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see
Southampton, GB
Size (employees)
12 (est)-7%
Synairgen is headquartered in Southampton, GB

Synairgen Office Locations

Synairgen has an office in Southampton
Southampton, GB (HQ)
Mailpoint 810 Southampton General Hospital Tremona Road

Synairgen Financials and Metrics

Synairgen Financials

Synairgen's revenue was reported to be £25 k in FY, 2015 which is a 99% decrease from the previous period.

Net income (FY, 2016)

(2.8 m)

EBITDA (FY, 2016)

(3.4 m)

EBIT (FY, 2016)

(3.4 m)

Market capitalization (31-Oct-2017)

11.9 m

Closing share price (31-Oct-2017)


Cash (31-Dec-2016)

3.1 m
Synairgen's current market capitalization is £11.9 m.
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


155 k4.3 m25 k

Revenue growth, %


Cost of goods sold

43 k

Gross profit

112 k
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


557 k6 m1.3 m1.5 m1.7 m1.3 m9.6 m4 m3.1 m

Accounts Receivable

39 k


103 k123 k293 k216 k72 k199 k56 k56 k55 k

Current Assets

4.5 m8.5 m5.8 m5.6 m3.4 m1.7 m9.8 m8.2 m5.5 m
    GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (2.2 m)(2.5 m)(2.6 m)(3.2 m)(2.3 m)(2 m)1.2 m(2.3 m)(2.8 m)

    Cash From Operating Activities

    (2.2 m)(2.4 m)(2.8 m)(2.6 m)(2.5 m)(1.8 m)1.8 m(1.9 m)(3 m)

    Cash From Financing Activities

    (3 k)6.2 m(3 k)2.5 m2.4 m6.5 m1 k

    Net Change in Cash

    (463 k)5.4 m(4.6 m)158 k760 k(822 k)2 m1.1 m(888 k)
      Y, 2016

      Financial Leverage

      1.2 x
      Show all financial metrics

      Synairgen Market Value History

      Synairgen's Web-traffic and Trends

      Synairgen Online and Social Media Presence

      Synairgen Company Life and Culture

      You may also be interested in